Due to a production error, there was a mistake in Figure 6 as published. Part of the y axis title and scale in Figure 6B was obscured by a white area.
The corrected Figure 6 appears below. The publisher apologizes for this mistake.
Figure 6
Boosting is required to generate virus neutralization after receiving trivalent vaccine. (A) Means of signals at different time points for HA0 and HA1 variants of H1, H5 and H7 after administration of trivalent vaccine. (B) HI assay titers of individual sera used in panels (A, B) against PR8 reassortant influenza viruses expressing Cal09 H1, VN04 H5 and AH13 H7, respectively. Horizontal dotted line, 1/40 dilution cutoff (log-2 of 40 = 5.32) (C) serial dilutions of plasma from a representative mouse to determine titers at different time points using microarrays; shown are means of H1, H5 and H7 variants after serial dilutions. All data are representative of two separate experiments. PB1, post first boost; PB2, post second boost; red arrows, boosts. ****P < 0.0001; ***P ≤ 0.001; **P ≤ 0.01; *P < 0.05.
The original version of this article has been updated.
Summary
Keywords
vaccine, influenza, adjuvant, CpG, MPLA, ADDAVAX®, hemagglutinin
Citation
Frontiers Production Office (2021) Erratum: Administration of Multivalent Influenza Virus Recombinant Hemagglutinin Vaccine in Combination-Adjuvant Elicits Broad Reactivity Beyond the Vaccine Components. Front. Immunol. 12:754535. doi: 10.3389/fimmu.2021.754535
Received
06 August 2021
Accepted
06 August 2021
Published
20 August 2021
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
12 - 2021
Updates
Copyright
© 2021 Frontiers Production Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org
This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.